||Recombinant human IRF4 (450 aa, derived from BC015752) fused with T7-His-TEV cleavage site Tag (29aa) at N-terminal was expressed in E. coli.
||0.50 mg/ml, sterile-filtered, in 20 mM pH 8.0 Tris-HCl Buffer, with proprietary formulation of NaCl, KCl, EDTA, Sucrose and DTT.
||MASMTGGQQMGRGHHHHHHENLYFQGGEFNLEGGGRGGEFGMSAVSCGNGKLRQWLIDQIDSGKYPGLVWENEEK SIFRIPWKHAGKQDYNREEDAALFKAWALFKGKFREGIDKPDPPTWKTRLRCALNKSNDFEELVERSQLDISDPY KVYRIVPEGAKKGAKQLTLEDPQMSMSHPYTMTTPYPSLPAQQVHNYMMPPLDRSWRDYVPDQPHPEIPYQCPMT FGPRGHHWQGPACENGCQVTGTFYACAPPESQAPGVPTEPSIRSAEALAFSDCRLHICLYYREILVKELTTSSPE GCRISHGHTYDASNLDQVLFPYPEDNGQRKNIEKLLSHLERGVVLWMAPDGLYAKRLCQSRIYWDGPLALCNDRP NKLERDQTCKLFDTQQFLSELQAFAHHGRSLPRFQVTLCFGEEFPDPQRQRKLITAHVEPLLARQLYYFAQQNSG HFLRGYDLPEHISNPEDYHRSIRHSSIQE
||>90% by SDS-PAGE
||1. May be used for in vitro IRF4 mediated gene transcription regulation for brown fat cell and macrophage interferon pathway study with "ProFectin" reagent based intracellular delivery of this protein.2. May be used as specific protein substrate for kinase and ubiquitin (Sumo pathway) related enzyme functional screening assays.3. May be used for IRF4 protein-protein interaction mapping.4. As immunogen for specific antibody production.
||Keep at -80centigrade for long term storage. Product is stable at 4 centigrade for at least 7 days.